This article was originally published in The Gray Sheet
Executive SummaryReinstates offer to merge with Kirschner, changing the amended proposal it withdrew July 1 to a definitive offer. The basic terms remain the same: each share of Kirschner common stock would be exchanged for 1.3 shares of Orthomet common stock and a seven-year warrant to buy an additional 1.3 shares of Orthomet common at an exercise price of $10 per share ("The Gray Sheet" July 4, p. 7). The offer expires at 5:00 p.m. Eastern Daylight Time on July 11. Kirschner must decide between the Orthomet deal and an offer from Biomet. Under the Biomet proposal, Kirschner shareholders could choose to receive either one Biomet common share (which has been trading for around $10), or $10 in cash, for each of their Kirschner common shares. Kirschner currently has 3,607,740 shares outstanding
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.